Crinetics Pharmaceuticals Prices $350M Public Offering at Discount to Market, Securing Significant Capital

summarizeSummary

Crinetics Pharmaceuticals announced the pricing of a public offering to raise up to $379.8 million, with shares priced at a discount to the current market, to fund commercial activities and R&D.

check_boxKey Events · Financing and Capital Events · CRNX

• Public Offering Priced

  Crinetics Pharmaceuticals priced an underwritten public offering of 7,620,000 shares of common stock at $45.95 per share.

• Underwriters' Option

  The company granted underwriters a 30-day option to purchase up to an additional 1,143,000 shares of common stock.

• Significant Net Proceeds

  The offering is expected to generate approximately $330.2 million in net proceeds, potentially rising to $379.8 million if the option is fully exercised.

• Use of Proceeds

  Proceeds will fund commercial activities for PALSONIFY™ launch, research and development of product candidates, other research programs, and general corporate purposes.

auto_awesomeAnalysis · CRNX · Life Sciences

Crinetics Pharmaceuticals has priced a substantial public offering, raising approximately $330.2 million, potentially increasing to $379.8 million if the underwriters' option is fully exercised. This capital raise is significant for a life sciences company, providing crucial funding for the commercial launch of PALSONIFY™, ongoing research and development, and general corporate purposes. While the offering is dilutive, the successful securing of such a large sum extends the company's financial runway. The pricing of the shares at $45.95, a discount to the current market price of $53.13, indicates the concessions made to attract investors for this capital infusion.